title: Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
abstract: This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate plus oral daily placebo or 2.5 mg/day oral risedronate, the licensed dose in Japan, plus IV placebo. The primary end point was noninferiority of ibandronate versus risedronate for first new or worsening vertebral fracture over 3 years. A total of 1,265 patients were randomized. A total of 1,134 patients formed the per-protocol set. Both ibandronate doses were noninferior to risedronate: 0.5 mg, hazard ratio (HR) 1.09 [95 % confidence interval (CI) 0.77-1.54]; 1 mg, HR 0.88 (95 % CI 0.61-1.27). The rate of first new vertebral fracture over 3 years was 16.8 % (95 % CI 12.8-20.8) for 0.5 mg ibandronate, 11.6 % (95 % CI 8.2-15.0) for 1 mg ibandronate, and 13.2 % (95 % CI 9.6-16.9) for risedronate. Significant increases in bone mineral density relative to baseline were observed with all treatments after 6 months, with substantial reductions in bone turnover markers after 3 months. Greatest efficacy was obtained with 1 mg ibandronate. Analyses in women only showed similar results to the overall population. No new safety concerns were identified. This study demonstrated the noninferiority of IV ibandronate to the licensed Japanese dose of oral risedronate and suggested that 1 mg/month is an effective dose in Japanese patients with primary osteoporosis.
authors: Department of Orthopedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan. t-nak@utopia.ocn.ne.jp
authors: Toshitaka
authors: T
authors: Nakamura
authors: Tetsuo
authors: T
authors: Nakano
authors: Masako
authors: M
authors: Ito
authors: Hiroshi
authors: H
authors: Hagino
authors: Junko
authors: J
authors: Hashimoto
authors: Masato
authors: M
authors: Tobinai
authors: Hideki
authors: H
authors: Mizunuma
mesh_terms: D000284:Administration, Oral; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D000077557:Ibandronic Acid; D007262:Infusions, Intravenous; D007564:Japan; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D016016:Proportional Hazards Models; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid
references: Osteoporos Int. 2003 May;14(3):225-34
references: 12730746
references: Osteoporos Int. 2002 Dec;13(12):971-9
references: 12459940
references: J Clin Endocrinol Metab. 2003 Feb;88(2):542-9
references: 12574177
references: Osteoporos Int. 2000;11(1):83-91
references: 10663363
references: J Bone Miner Metab. 2001;19(6):331-7
references: 11685647
references: Osteoporos Int. 2012 Jun;23(6):1747-56
references: 21953471
references: J Bone Miner Res. 2004 Aug;19(8):1241-9
references: 15231010
references: N Engl J Med. 2001 Feb 1;344(5):333-40
references: 11172164
references: Curr Med Res Opin. 2005 Mar;21(3):391-401
references: 15811208
references: J Bone Miner Res. 2005 Aug;20(8):1315-22
references: 16007327
references: J Bone Miner Res. 2003 Aug;18(8):1547-53
references: 12929946
references: Bone. 2010 Apr;46(4):970-6
references: 20060082
references: J Bone Miner Res. 2005 Jul;20(7):1185-94
references: 15940371
references: J Bone Miner Res. 1996 Jul;11(7):984-96
references: 8797120
references: JAMA. 1999 Oct 13;282(14):1344-52
references: 10527181
references: Curr Med Res Opin. 2010 Mar;26(3):599-604
references: 20055751
references: Osteoporos Int. 2012 Feb;23(2):695-703
references: 21394496
references: Osteoporos Int. 2012 Jun;23(6):1769-78
references: 21975558
references: J Rheumatol. 2008 Mar;35(3):488-97
references: 18260172
references: J Clin Invest. 2005 Dec;115(12):3318-25
references: 16322775
references: J Bone Miner Metab. 2004;22(2):111-9
references: 14999521
references: Bone. 2009 Mar;44(3):423-7
references: 19049913
references: J Bone Miner Metab. 2004;22(5):469-78
references: 15316868
references: Clin Rheumatol. 2008 Aug;27(8):955-60
references: 18180976
references: J Clin Densitom. 2008 Jul-Sep;11(3):417-23
references: 18456528
references: Bone. 2010 Mar;46(3):660-5
references: 19909829
references: J Bone Miner Metab. 2006;24(5):405-13
references: 16937274
references: Bone. 2004 May;34(5):890-9
references: 15121021
references: Ann Rheum Dis. 2006 May;65(5):654-61
references: 16339289
references: Osteoporos Int. 2009 Feb;20(2):291-7
references: 18663402